Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
| Image |  |
|---|---|
| Description | scientific article published on 23 December 2017 |
| Author/s |
author: James M Ford Melinda L Telli |
| Publication date | December 23, 2017 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |